Hoth Therapeutics Inc

HOTH

Company Profile

  • Business description

    Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

  • Contact

    1177 Avenue of the Americas
    5th Floor, Suite 5066
    New YorkNY10036
    USA

    T: +1 646 756-2997

    https://www.hoththerapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    3

Stocks News & Analysis

stocks

Meta earnings: Strong end to 2025 as AI monetization begins to show

Investors please with latest results.
stocks

Why doesn’t the market like the earnings from this US tech giant?

Good quarter with AI demand ramping.
stocks

Our Tesla fair value increases meaningfully

Progress on Robotaxi and Optimus shows real world AI growth.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,236.906.40-0.07%
CAC 408,139.8373.150.91%
DAX 4024,585.99236.80-0.95%
Dow JONES (US)49,015.6012.190.02%
FTSE 10010,261.44107.011.05%
HKSE27,968.09141.180.51%
NASDAQ23,857.4540.350.17%
Nikkei 22553,375.6016.890.03%
NZX 50 Index13,348.6164.26-0.48%
S&P 5006,978.030.000.00%
S&P/ASX 2008,927.504.300.05%
SSE Composite Index4,157.986.750.16%

Market Movers